This press release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate," "intend,"
"plan," "may," "will," "could," "should," "believes," "predicts,"
"potential," "continue," and similar expressions are intended to identify
such forward-looking statements. Forward- looking statements in this press
release include matters that involve known and unknown risks, uncertainties
and other factors that may cause actual results, levels of activity,
performance or achievements to differ materially from results expressed or
implied by this press release. Such risk factors include, among others:
whether Zingo gains FDA approval in the adult indication, the degree to
which Zingo gains market acceptance, and whether the Adlea clinical trials
will be successful. Actual results may differ materially from those
contained in the forward-looking statements in this press release.
Additional information concerning these and other risk factors is contained
in Anesiva's annual report on Form 10-K for the year ended December 31,
2007, and its most recent filing on Form 10-Q.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
For the three months For the six months
ended June 30, ended June 30,
2008 2007 2008 2007
Contract revenues $302 $- $303 $-
Manufacturing start-up costs 1,125 - 1,125 -
Research and development 13,063 8,412 26,447 15,374
Sales, general and
|SOURCE Anesiva, Inc.|
Copyright©2008 PR Newswire.
All rights reserved